COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
Remdesivir meta
6/29 Late treatment study
Zhu et al., medRxiv, doi:10.1101/2020.06.22.20136531 (Peer Reviewed) (meta analysis)
Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
Source   PDF   Share   Tweet
Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175).

Zhu et al., 6/29/2020, peer-reviewed, 11 authors.
risk of death, 36.0% lower, RR 0.64, p = 0.02.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 16 studies
Please send us corrections, updates, or comments.
Submit